Full-Time

Field Service Representative II

Cardiopulmonary

LivaNova

LivaNova

1,001-5,000 employees

Global cardiopulmonary and neuromodulation devices

Compensation Overview

$75k - $85k/yr

+ Bonus

Minneapolis, MN, USA

In Person

75% travel; on-site in the Minneapolis area.

Category
Biology & Biotech (1)

Get referred to LivaNova

See people who can refer or advise you

Requirements
  • Requires high level of organizational and territory management skills.
  • Demonstrated ability to manage self.
  • Requires consistent performance in the ability to use logical methods to identify and solve equipment related problems.
  • Demonstrated strong interactive people skills, a high degree of customer relations skills and the ability to relate well to a wide variety of people.
  • Strong focus on customer relations and timely resolution of problems.
  • Demonstrated accountability for field service administrative tasks.
  • Strong analytical and problem solving skills relating to solving equipment problems.
  • Stand 90% / Sit/Walk 10%
  • Availability for call 24/7
  • Lift 0-50 lbs
  • Grip, grasp, push, pull
  • Kneel, stoop, bend, twist, reach above the shoulders
  • Repetitive use on computer
  • Pinch repetitively
  • Oral Comprehension
  • Communication Skills
  • Written Comprehension
  • Mathematical Reasoning
  • Memorization
  • Spatial Orientation
  • Blood borne pathogen exposure
  • Around 75% travel
  • Requires 2 years of Technical College or equivalent
  • Minimum of 3 years as a Field Service Representative or Hospital Technician
Responsibilities
  • Performs preventive maintenance within scheduled time frames on equipment in assigned territory.
  • Sells service business within the territory as appropriate and works closely with sales to continue a strong LIVANOVA presence in territory.
  • Provides corrective maintenance on equipment within assigned territory.
  • Ensures quality standards are met or exceeded in the performance of services provided.
  • Responsible and accountable for all assigned company assets including tools, test equipment, inventory, computers, pagers, corporate cards, documentation, “intellectual property”, etc.
  • Completes timely paper work, documentation, and administrative tasks per organizational policy and procedures.
  • Maintains an action plan of personal development and training through goals and objectives to improve job skills and overall industry and product knowledge.
  • Responsible for maintaining financial cost effectiveness within the assigned territory.
  • Works effectively with coworkers, other departments and customers.
  • Communicates accurate technical findings to enable thorough analysis of problems, root causes and resolutions.
  • Performs other additional duties or projects as assigned.

LivaNova focuses on cardiopulmonary and neuromodulation medical technologies, delivering devices and therapies for heart and brain conditions. Its products, used in hospitals worldwide, include implants and related treatments that aim to improve patient health while providing clinical and economic value to healthcare systems. The company differentiates itself with a diverse, integrated portfolio backed by decades of experience and a global reach, aligning clinical outcomes with economic impact. Its goal is to improve patients’ lives by delivering meaningful health benefits and helping providers achieve better value.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

2015

Get referred to LivaNova

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $390.6 million, with 10.8% reported growth and raised guidance.
  • PolySync lifted OSA response to 84.5%, supporting commercial conversion from nonresponders.
  • LivaNova plans a 2027 MRI-compatible aura6000 launch, extending its sleep franchise.

What critics are saying

  • SNIA environmental liability stands at €337.8 million, despite a €157.3 million reversal.
  • 3T device litigation still covers about 65 claims worldwide and drains management time.
  • Third-party component shortages constrain Essenz expansion, risking share loss to Getinge and Medtronic.

What makes LivaNova unique

  • Essenz heart-lung systems and consumables anchor LivaNova's cardiopulmonary moat across hospitals.
  • aura6000 became the first U.S.-approved hypoglossal therapy without collapse warning language in March 2026.
  • CORE-VNS showed 80% median seizure reduction at 36 months, strengthening epilepsy credibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Employee Stock Purchase Plan

Flexible Work Hours

Paid Vacation

Company News

Business Wire
Jun 16th, 2026
LivaNova's PolySync programming achieves 84.5% response rate in obstructive sleep apnoea study

LivaNova has announced that its PolySync programming algorithm achieved an 84.5% cumulative response rate in patients with moderate to severe obstructive sleep apnea treated with proximal hypoglossal nerve stimulation. The findings were presented at SLEEP 2026 by lead author Alan Schwartz. The results build on LivaNova's OSPREY trial, which reported a 65% responder rate after 12 months. In the PolySync substudy, patients who initially did not respond underwent reprogramming using simultaneous-contact stimulation, converting most into responders and significantly improving outcomes. The approach was well tolerated with no serious adverse events. PolySync will be available with LivaNova's commercial product. The company is preparing its next-generation obstructive sleep apnea device for FDA submission in the second half of 2026, featuring MRI compatibility and rechargeable battery technology.

Business Wire
Jun 11th, 2026
Jette Nygaard-Andersen joins LivaNova board as medtech company reshuffles directors

LivaNova, a medical technology company, has appointed Jette Nygaard-Andersen to its Board of Directors following its Annual General Meeting on 10 June. Nygaard-Andersen currently chairs Coloplast A/S, a Danish medical device company, and previously served as CEO of Entain plc and in senior roles at Modern Times Group AB. The appointment coincides with Dr Sharon O'Kane stepping down after 10 years on the board. Brooke Story will succeed O'Kane as Chair of the Nominating and Corporate Governance Committee, whilst Peter Wilver assumes leadership of the Compensation and Human Capital Management Committee. LivaNova develops medical solutions for neurological and cardiac conditions, employs approximately 3,300 people, and operates in over 100 countries.

Yahoo Finance
May 6th, 2026
LivaNova posts 10% organic growth in Q2 driven by cardiopulmonary momentum and neuromodulation gains

LivaNova reported 10% organic revenue growth in Q2 2025, driven by cardiopulmonary business momentum and solid neuromodulation performance across all regions. The company also delivered operating margin expansion and strong cash generation. The company announced key clinical milestones, including long-term results from the CORE-VNS study showing an 80% median seizure reduction at 36 months for focal onset seizures and 95% for focal to bilateral tonic-clonic seizures in drug-resistant epilepsy patients. LivaNova initiated the process with CMS to seek national Medicare coverage for VNS therapy in treatment-resistant depression patients, supported by five peer-reviewed publications from the RECOVER study. The company's obstructive sleep apnea programme remains in FDA review, with management expressing confidence in its proximal hypoglossal nerve stimulation technology.

Yahoo Finance
May 6th, 2026
LivaNova posts 13% organic revenue growth in Q3, driven by cardiopulmonary surge and epilepsy gains

LivaNova reported 13% organic revenue growth in Q3 2025, driven by strong performance in cardiopulmonary and epilepsy businesses. The cardiopulmonary segment generated $203 million in revenue, up 16% year-over-year, with heart-lung machine revenue growing over 20%. The company saw accelerated placements of its Essenz heart-lung machines, with most installations in developed markets. LivaNova launched Essenz in China, its second-largest market, in August, with positive early feedback. However, expansion remains constrained by third-party component supply despite progressing manufacturing capacity plans. LivaNova unveiled a refreshed brand identity and new strategic framework, which will be detailed at its investor day on 12 November. The company is focusing on near-term performance whilst investing in core businesses and developing programmes for obstructive sleep apnoea.

Yahoo Finance
May 6th, 2026
LivaNova beats Q1 expectations with $362.3M revenue but shares slip 2% on cautious guidance

LivaNova reported first-quarter results that exceeded Wall Street expectations, but shares fell more than 2% in premarket trading as investors reacted cautiously to guidance. The medical technology company posted adjusted earnings per share of $0.98, beating analyst estimates of $0.90, whilst revenue reached $362.3 million, surpassing the $346.06 million consensus. The company raised its full-year 2026 revenue growth guidance to 7.0%–8.0% on a constant-currency basis, up from 6.0%–7.0% previously. Adjusted diluted EPS guidance increased to $4.20–$4.30 from $4.15–$4.25. However, the $4.25 midpoint only marginally exceeded analyst consensus of $4.21. Revenue growth was driven by the Cardiopulmonary division, which rose 18.3% to $208.7 million, and Neuromodulation, which climbed 9.3% to $151.8 million.